Publications by authors named "Michael J Strunc"
Article Synopsis
- - Narcolepsy and idiopathic hypersomnia are chronic sleep disorders that hinder alertness and overall quality of life, and low-sodium oxybate (LXB) is a treatment option approved for these conditions, particularly effective for symptoms like cataplexy and excessive daytime sleepiness.
- - LXB has a similar safety profile to sodium oxybate (SXB) and offers additional benefits such as flexible dosing, improved quality of life, potential weight loss, and reduced sodium intake, which may help mitigate health risks associated with these sleep disorders.
- - Patients transitioning from SXB to LXB typically start at the same dosage, allowing for manageable adjustments over time, and studies suggest that LXB can lead to improved functioning and health
Background: Sodium oxybate, which is approved for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy, is available in the USA only through the restricted-distribution Xyrem Risk Evaluation and Mitigation Strategy Program (Xyrem REMS Program, XRP). The XRP requires prescriber enrollment and certification, patient enrollment, and prescriber attestation of patient counseling. Sodium oxybate is dispensed only by the certified pharmacy.
View Article and Find Full Text PDF